ArticleOncotarget2017

Ruxolitinib combined with vorinostat suppresses tumor growth and alters metabolic phenotype in hematological diseases.

Monica Civallero et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.